Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

1.

Estimates of Medication Expenditure for Ischemic Heart Disease Accompanying Chronic Obstructive Pulmonary Disease.

Rysiak E, Prokop I, Zaręba I, Mróz RM.

Adv Exp Med Biol. 2018 Apr 21. doi: 10.1007/5584_2018_201. [Epub ahead of print]

PMID:
29679364
2.

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.

Beier J, Mroz R, Kirsten AM, Chuecos F, Gil EG.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 14;12:1731-1740. doi: 10.2147/COPD.S121723. eCollection 2017.

3.

Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project.

Niklinski J, Kretowski A, Moniuszko M, Reszec J, Michalska-Falkowska A, Niemira M, Ciborowski M, Charkiewicz R, Jurgilewicz D, Kozlowski M, Ramlau R, Piwkowski C, Kwasniewski M, Kaczmarek M, Ciereszko A, Wasniewski T, Mroz R, Naumnik W, Sierko E, Paczkowska M, Kisluk J, Sulewska A, Cybulski A, Mariak Z, Kedra B, Szamatowicz J, Kurzawa P, Minarowski L, Charkiewicz AE, Mroczko B, Malyszko J, Manegold C, Pilz L, Allgayer H, Abba ML, Juhl H, Koch F; MOBIT Study Group.

Adv Med Sci. 2017 Sep;62(2):405-413. doi: 10.1016/j.advms.2017.05.002. Epub 2017 Jun 21.

PMID:
28646744
4.

Biological effects of gold mine tailings on the intertidal marine environment in Nova Scotia, Canada.

Doe K, Mroz R, Tay KL, Burley J, Teh S, Chen S.

Mar Pollut Bull. 2017 Jan 15;114(1):64-76. doi: 10.1016/j.marpolbul.2016.08.056. Epub 2016 Oct 3.

PMID:
27697321
5.

Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.

Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA, Buaron KS, Yun Kirby S, Pascoe SJ; VESTRI Investigators.

N Engl J Med. 2016 Sep 1;375(9):840-9. doi: 10.1056/NEJMoa1606356.

6.

Neuroinfection as a Mask of Lung Cancer: A Case Series.

Kuklińska B, Moniuszko-Malinowska A, Mróz R, Pancewicz S, Zajkowska J.

Case Rep Infect Dis. 2016;2016:6061350. doi: 10.1155/2016/6061350. Epub 2016 Apr 30.

7.

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators.

N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15.

8.

EVALUATION OF THE TREATMENT COSTS OF ASTHMA EXACERBATIONS IN OUTPATIENTS.

Rysiak E, Kuczyńska A, Zareba I, Mróz R, Pałka J.

Acta Pol Pharm. 2016 Jan-Feb;73(1):239-45.

PMID:
27008818
9.

Costs of Treatment of Chronic Obstructive Pulmonary Disease.

Milewska A, Rysiak E, Zareba I, Holownia A, Mroz RM.

Adv Exp Med Biol. 2016;885:67-75. doi: 10.1007/5584_2015_199.

PMID:
26801145
10.

Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study.

Mroz RM, Lisowski P, Tycinska A, Bierla J, Trzeciak PZ, Minarowski L, Milewski R, Lisowska A, Boros P, Sobkowicz B, Duszewska AM, Chyczewska E, Musial WJ, MacNee W.

J Physiol Pharmacol. 2015 Feb;66(1):111-28.

11.

Tregs and HLA-DR expression in sputum cells of COPD patients treated with tiotropium and formoterol.

Holownia A, Wielgat P, Stasiak-Barmuta A, Kwolek A, Jakubow P, Szepiel P, Chyczewska E, Braszko JJ, Mroz RM.

Adv Exp Med Biol. 2015;839:7-12. doi: 10.1007/5584_2014_43.

PMID:
25315616
12.

Inhaled corticosteroids increase siglec-5/14 expression in sputum cells of COPD patients.

Wielgat P, Mroz RM, Stasiak-Barmuta A, Szepiel P, Chyczewska E, Braszko JJ, Holownia A.

Adv Exp Med Biol. 2015;839:1-5. doi: 10.1007/5584_2014_51.

PMID:
25252903
13.

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators.

N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8.

14.

[Influence of inhaler and fine particle on efficacy of inhalation therapy in COPD].

Sliwiński P, Chazan R, Dąbrowiecki P, Jahnz-Różyk K, Mróz R, Pirożyński M.

Pneumonol Alergol Pol. 2014;82(3):300-10. doi: 10.5603/PiAP.2014.0035. Review. Polish.

15.

Histone acetylation and arachidonic acid cytotoxicity in HepG2 cells overexpressing CYP2E1.

Holownia A, Mroz RM, Wielgat P, Jakubow P, Jablonski J, Sulek J, Braszko JJ.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Mar;387(3):271-80. doi: 10.1007/s00210-013-0942-4. Epub 2013 Nov 28.

16.

Tiotropium Respimat inhaler and the risk of death in COPD.

Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators.

N Engl J Med. 2013 Oct 17;369(16):1491-501. doi: 10.1056/NEJMoa1303342. Epub 2013 Aug 30.

17.

Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease.

Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EF, Agustí A, Fabbri LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, Silverman EK, Mayer RJ, Pillai SG; TESRA and ECLIPSE Investigators.

Am J Respir Crit Care Med. 2013 Oct 15;188(8):948-57. doi: 10.1164/rccm.201302-0247OC.

PMID:
23947473
18.

Siglec-8 in induced sputum of COPD patients.

Mroz RM, Holownia A, Wielgat P, Sitko A, Skopinski T, Chyczewska E, Braszko JJ.

Adv Exp Med Biol. 2013;788:19-23. doi: 10.1007/978-94-007-6627-3_3.

PMID:
23835953
19.

Altered histone deacetylase activity and iNOS expression in cells isolated from induced sputum of COPD patients treated with tiotropium.

Holownia A, Mroz RM, Wielgat P, Skopinski T, Kolodziejczyk A, Sitko A, Chyczewska E, Braszko JJ.

Adv Exp Med Biol. 2013;788:1-6. doi: 10.1007/978-94-007-6627-3_1.

PMID:
23835951
20.

Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.

Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, Gil EG.

COPD. 2013 Aug;10(4):511-22. doi: 10.3109/15412555.2013.814626. Epub 2013 Jul 2.

Supplemental Content

Loading ...
Support Center